Last reviewed 2026-04-20 · How we verify

Immediate-Release Tablets

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Diarrhoea
• COVID-19
• Hyperkalaemia
• Dizziness
• Hypotension
• Renal impairment
• Hypertension
• Anaemia
• Glomerular filtration rate decreased
• Urinary tract infection
• Thirst
• Polyuria

Key clinical trials

• Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease (PHASE2)
• Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (PHASE3)
• A Study of Idazoxan in Healthy Participants (PHASE1)
• Oxybutynin ER to Promote Early Continence Recovery After Robotic Prostatectomy: A Randomized Controlled Trial (NA)
• ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD) (PHASE2)
• A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation. (PHASE1)
• A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) (PHASE3)
• Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart Failure (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Immediate-Release Tablets CI brief — competitive landscape report
• Immediate-Release Tablets updates RSS · CI watch RSS
• West China Second University Hospital portfolio CI